{
    "Project Title": "Trelagliptin-4002",
    "Sponsor": "Not Available",
    "Study Number": "Not Available",
    "Protocol Version and Date": "Version 2.0 July 5, 2017",
    "Study Title": "Trelagliptin-4002",
    "Phase": "Phase III",
    "Therapeutic Area": "Diabetes (Type 2)",
    "Number of Patients": "240",
    "Number of Sites": "Approximately 15",
    "Indication": "Assessment of reduction in treatment burden during 12 weeks of trelagliptin administration in patients with type 2 diabetes",
    "Duration of Treatment": "12 weeks",
    "Schedule of Assessments": "Not Available",
    "questionnaires": [
        {
            "longName": "Diabetes Therapy-Related Quality of Life Questionnaire",
            "shortName": "DTR-QOL",
            "type": "Patient-Reported Outcome (PRO)",
            "questionnaireSchedule": "Screening period, Week 0, Week 4, Week 12"
        },
        {
            "longName": "Diabetes Treatment Satisfaction Questionnaire",
            "shortName": "DTSQ",
            "type": "Patient-Reported Outcome (PRO)",
            "questionnaireSchedule": "Screening period, Week 0, Week 4, Week 12"
        },
        {
            "longName": "The Basic Information on Study Subject",
            "shortName": "Your Basic Profile",
            "type": "None of the above",
            "questionnaireSchedule": "Screening period, Week 0, Week 4, Week 12"
        }
    ]
}